全文获取类型
收费全文 | 71766篇 |
免费 | 5846篇 |
国内免费 | 3294篇 |
专业分类
耳鼻咽喉 | 203篇 |
儿科学 | 1332篇 |
妇产科学 | 833篇 |
基础医学 | 12804篇 |
口腔科学 | 774篇 |
临床医学 | 5569篇 |
内科学 | 16791篇 |
皮肤病学 | 1103篇 |
神经病学 | 2690篇 |
特种医学 | 1297篇 |
外国民族医学 | 9篇 |
外科学 | 3901篇 |
综合类 | 10592篇 |
现状与发展 | 19篇 |
预防医学 | 6011篇 |
眼科学 | 492篇 |
药学 | 8892篇 |
18篇 | |
中国医学 | 3544篇 |
肿瘤学 | 4032篇 |
出版年
2023年 | 803篇 |
2022年 | 1862篇 |
2021年 | 2296篇 |
2020年 | 2160篇 |
2019年 | 2397篇 |
2018年 | 2281篇 |
2017年 | 2248篇 |
2016年 | 2616篇 |
2015年 | 2879篇 |
2014年 | 4669篇 |
2013年 | 4897篇 |
2012年 | 4798篇 |
2011年 | 5109篇 |
2010年 | 4135篇 |
2009年 | 3940篇 |
2008年 | 3894篇 |
2007年 | 3787篇 |
2006年 | 3460篇 |
2005年 | 2949篇 |
2004年 | 2449篇 |
2003年 | 2115篇 |
2002年 | 1723篇 |
2001年 | 1512篇 |
2000年 | 1176篇 |
1999年 | 1022篇 |
1998年 | 940篇 |
1997年 | 786篇 |
1996年 | 660篇 |
1995年 | 670篇 |
1994年 | 572篇 |
1993年 | 471篇 |
1992年 | 447篇 |
1991年 | 353篇 |
1990年 | 321篇 |
1989年 | 286篇 |
1988年 | 243篇 |
1987年 | 205篇 |
1986年 | 172篇 |
1985年 | 445篇 |
1984年 | 462篇 |
1983年 | 372篇 |
1982年 | 382篇 |
1981年 | 318篇 |
1980年 | 296篇 |
1979年 | 262篇 |
1978年 | 205篇 |
1977年 | 160篇 |
1976年 | 176篇 |
1975年 | 154篇 |
1974年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
周天保 《中华移植杂志(电子版)》2019,13(3):252-254
目前,国内外肝移植学界对肝移植术后急性排斥反应(AR)的机制阐释为T细胞介导的细胞免疫应答,但为获得长期生存仍需长期乃至终身服用免疫抑制剂。即使如此,临床上AR仍时有发生,并导致相当一部分受者移植肝功能丧失,更重要的是受者术后还受到感染、肿瘤和其他一系列不良反应及沉重经济负担的影响。因此,为肝移植AR机制提出新的理论解释,更全面深入阐明肝移植免疫排斥反应的内在机制,进而依据新的机制研制出新型免疫抑制剂已势在必行。本文就B细胞介导的体液免疫应答在肝移植AR中的作用作一综述。 相似文献
3.
4.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
5.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
6.
This study aimed to observe the therapeutic effects of magnesium lithospermate B on acute and chronic colitis induced by dextran sodiumsulfate (DSS) and the role of inflammasome complex (NOD-like receptor protein, NLRP; apoptosis-associated speck-like protein containing, ASC; caspase-1). Establishment of acute and chronic colitis models were by using 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (240 mg/kg body weight) was given by subcutaneous injection. Samples were collected for biomarker assay, histological examination, immunohistochemical evaluation and western blot. There was obvious increase in TNF-α level and NLPR3, ASC, and caspase-1 expressions in acute and chronic colitis groups compared with the normal control. Significant decrease of the tumor necrosis factor-α level and the expressions of NLPR3, ASC, and caspase-1 were observed after treatment with magnesium lithospermate B. This study showed that magnesium lithospermate B could be used to treat acute and chronic colitis by inhibiting the activation of the NLRP3/ASC/Caspase-1 pathway. 相似文献
7.
Flavia Temperilli Aldona Rina Isabella Massimi Anna Lisa Montemari Maria Luisa Guarino Alessandra Zicari 《Platelets》2015,26(8):783-787
Serum thromboxane-B2 (TxB2), together with arachidonic acid (AA)-induced platelet aggregation, are, at the moment, the most used tests to identify patients displaying high on-aspirin treatment platelet reactivity (HAPR). Both tests are specific for aspirin action on cyclooxygenase-1. While the correlation between serum TxB2 assay and clinical outcome is established, data are conflicting with regard to aspirin treatment and a possible association with AA-stimulated platelet markers and clinical outcome. To understand such discrepancy, we performed a retrospective study to compare both assays. We collected data from 132 patients receiving a daily dose of aspirin (100?mg/day) and data from 48 patients receiving aspirin on alternate days. All Patients who received a daily dose of aspirin were studied for AA-induced platelet aggregation together with serum TxB2 levels and AA-induced TxB2 formation was also studied in 71 patients out of entire population. Consistent with recommendations in the literature, we defined HAPR by setting a cut-off point at 3.1?ng/ml for serum levels of thromboxane B2 and 20% for AA-induced platelet aggregation. According to this cut-off point, we divided our overall population into two groups: (1) TxB2?<?3.1?ng/ml and (2) TxB2?>?3.1?ng/ml. We found low agreement between such tests to identify patients displaying HAPR. Our results show that AA-induced platelet aggregation >20% identify a smaller number of HAPR patients in comparison with TxB2. A good correlation between serum TxB2 and arachidonic acid-induced TxB2 production was found (r?=?0.76619). 相似文献
8.
9.
目的 分析CSTB、A-FABP在膀胱癌诊断和预后的意义。方法 选取2014年1月至2016年7月在本院进行手术、病理证实的膀胱癌患者45例、良性膀胱病变患者88例,检测膀胱癌样本癌组织、癌旁组织、良性膀胱病变组织中CSTB、A-FABP表达水平。评价CSTB、A-FABP在鉴别诊断膀胱癌的效用。对比膀胱癌进展对象(2年内转移、复发、肿瘤死亡)以及未进展对象组织中CSTB、A-FABP表达水平。结果 癌组织、癌旁组织、良性病变对象组织中CSTB、A-FABP表达水平差异有统计学意义(P<0.05)。CSTB、A-FABP作为诊断标准(任意一项为阳性),鉴别诊断膀胱癌与良性病变的灵敏度为84.4%、特异度为90.9%、阳性预测值82.6%、阴性预测值92.0%、符合率88.7%。2年内转移、复发、肿瘤死亡的患者共30例,无转移、复发、死亡的患者共15例,膀胱癌进展对象CSTB、A FABP表达量高于未进展对象,差异有统计学意义(P<0.05)。结论 CSTB、A-FABP在膀胱癌诊断、预后预测中均有一定的临床价值。 相似文献
10.